| Literature DB >> 28331773 |
Christian R Mejia1, Virgilio E Failoc-Rojas2, Edison So3, Carmen Cervantes4, Antonio J Aspajo5, Jesus Galileo Leandro6, Jhomar Cordova-De La Cruz6, Julio C Charri6, Kevin E García-Auqui7, Lelis Gabriela Coronel-Chucos8, Luz Delia Justo-Pinto9, Marisol Stefanie Mamani-Apaza9, Neil Arón Paz-Campos10, Ricardo Correa11.
Abstract
INTRODUCTION: Hypertension is a very common disease worldwide, and medication is needed to prevent its short-term and long-term complications. Our objective was to determine the characteristics and factors associated with antihypertensive medication use in patients attending Peruvian health facilities. MATERIALS &Entities:
Keywords: hypertension; multicenter; peru; pharmacologic treatment
Year: 2017 PMID: 28331773 PMCID: PMC5338991 DOI: 10.7759/cureus.1011
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Characteristics of the respondents and the antihypertensive treatment they received
*Median and range
HTN = hypertension; ARA-II = angiotensin II receptor antagonist; ACE = angiotensin converting enzyme
| Variable | N | % |
| Gender | ||
| Female | 547 | 61.2 |
| Male | 347 | 38.8 |
| Age (years)* | 57 | 18-93 |
| Receives anti-HTN treatment | ||
| Yes | 503 | 60.5 |
| No | 329 | 39.5 |
| Number of anti-HTN drugs | ||
| 1 | 414 | 82.8 |
| 2 | 75 | 15 |
| 3 | 8 | 1.6 |
| 4 | 3 | 0.6 |
| Had anti-HTN treatment today | ||
| Yes | 258 | 51.7 |
| No | 241 | 48.3 |
| Type of drug | ||
| ARA-II | 93 | 18.6 |
| Beta blocker | 15 | 3 |
| Calcium antagonist | 23 | 4.6 |
| ACE inhibitor | 288 | 57.6 |
| Thiazide | 10 | 2 |
| ARA-II + beta blocker | 3 | 0.6 |
| ARA-II + calcium antagonist | 15 | 3 |
| ARA-II + thiazide | 5 | 1 |
| ARA-II + ACE inhibitor | 8 | 1.6 |
| ACE + beta blocker | 3 | 0.6 |
| ACE + calcium antagonist | 8 | 1.6 |
| ACE + thiazide | 18 | 3.6 |
| Triple therapy, quadruple therapy | 8, 3 | 1.6, 0.6 |
Figure 1Percentage of people taking antihypertensive treatment related to comorbidities
Bivariate analysis of factors associated with receiving antihypertensive treatment
Confidence interval (95% CI) and p value obtained from generalized linear models with Poisson distribution, log link function, and headquarters of the respondent as clusters.
HTN = hypertension; cPR = crude prevalence ratio
*Mean and standard deviation
| Variable | Patients with HTN N (%) | cPR (95% CI) |
| |||||
| With treatment | Without treatment | |||||||
| Gender | ||||||||
| Female | 306 (60.8) | 202 (61.4) | 0.99 (0.77-1.28) | 0.943 | ||||
| Male | 197 (39.2) | 127 (38.6) | ||||||
| Age (years)* | 60.2 (15.0) | 50.4 (16.4) | 1.02 (1.01-1.03) | <0.001 | ||||
| Diabetes mellitus | ||||||||
| Diagnosed | 106 (21.1) | 26 (7.9) | 1.42 (1.23-1.63) | 0.001 | ||||
| Receives treatment | 94 (18.7) | 16 (4.9) | 1.51 (1.25-1.82) | <0.001 | ||||
| Heart disease | ||||||||
| Diagnosed | 138 (27.4) | 22 (6.7) | 1.59 (1.40-1.80) | <0.001 | ||||
| Receives treatment | 112 (22.3) | 11 (3.3) | 1.65 (1.45-1.88) | <0.001 | ||||
| Hypercholesterolemia | ||||||||
| Diagnosed | 160 (31.8) | 67 (20.4) | 1.24 (1.04-1.49) | 0.017 | ||||
| Receives treatment | 105 (20.9) | 30 (9.1) | 1.36 (1.23-1.52) | <0.001 | ||||
| Hypertriglyceridemia | ||||||||
| Diagnosed | 130 (25.9) | 53 (16.1) | 1.24 (1.01-1.52) | 0.043 | ||||
| Receives treatment | 86 (17.2) | 22 (6.7) | 1.39 (1.25-1.53) | <0.001 | ||||
| Other disease | ||||||||
| Chronic | 231 (48.3) | 147 (46.8) | 1.02 (0.88-1.20) | 0.764 | ||||
| Cardiovascular | 43 (9.0) | 20 (6.4) | 1.14 (0.94-1.39) | 0.181 | ||||
| Performs | ||||||||
| Physical activity | 137 (27.2) | 155 (47.1) | 0.69 (0.58-0.82) | <0.001 | ||||
| Any sport | 72 (14.3) | 89 (27.1) | 0.70 (0.54-0.89) | 0.004 | ||||
Multivariate analysis of factors associated with receiving antihypertensive treatment
Confidence interval (95% CI) and p value obtained from generalized linear models with Poisson distribution, log link function, and headquarters of the respondent as clusters.
aPR = adjusted prevalence ratio
*Mean and standard deviation
| Variable | aPR (95% CI) | p value |
| Age (years)* | 1.01 (1.007-1.017) | <0.001 |
| Receives treatment for: | ||
| Diabetes mellitus | 1.31 (1.11-1.55) | 0.001 |
| Heart disease | 1.38 (1.26-1.51) | <0.001 |
| Hypercholesterolemia | 1.08 (0.90-1.29) | 0.398 |
| Hypertriglyceridemia | 1.16 (0.98-1.37) | 0.075 |
| Performs physical activity | 0.80 (0.70-0.92) | 0.001 |